logo
Share SHARE
FONT-SIZE Plus   Neg

Forest Labs., Gedeon Report Results From 2 Phase III Trials Of Cariprazine

Forest Laboratories, Inc. (FRX) and Gedeon Richter Plc announced positive top-line results in 2 Phase III clinical trials of cariprazine (RGH-188) for treating acute exacerbation of schizophrenia.

For the primary endpoint in each study, the Positive And Negative Syndrome Scale, the data showed that cariprazine-treated patients experienced significant symptom improvement compared to placebo-treated patients.

Besides, all doses showed statistically significant separation from placebo starting at week 2 and at each subsequent time point with the higher dose showing separation as early as week 1 of treatment. Further analyses of the data in each study will be completed in the coming weeks.

Forest Labs noted that the results of these 2 studies were consistent with the results of the previously completed placebo-controlled Phase IIb fixed-dose study in this population.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Volkswagen AG's all electric Microbus might be available in market by 2022. As per the plan it would be available first in California. Microsoft Corp. has unveiled a new Minecraft limited edition version of the Xbox One S console during its Gamescom press conference in Germany. The pixelated device comes with 1TB of storage. It includes a custom designed grass block console, Xbox Wireless Controller - Minecraft Creeper, Minecraft system sounds, vertical stand and transparent underside with Redstone circuit accents. HTC Corp. has cut the price of its Vive virtual reality headset by $200, bringing down the system's cost to $599. The company noted that the new entry price will make the system more accessible to the mass market across the globe. The price cut for the Vive VR headset comes after the Oculus Rift's $200 price cut recently.
comments powered by Disqus
Follow RTT